Only in Titles

Search results for: O-Acetyl-L-homoserine Hydrochloride, 95% C6H12ClNO4 CAS: 250736-84-6

paperclip

#30604066   2019/01/02 To Up

Knockdown of KDM2A inhibits proliferation associated with TGF-β expression in HEK293T cell.

Lysine-specific demethylase 2A (KDM2A, also known as JHDM1A or FBXL11) plays an important role in regulating cell proliferation. However, the mechanisms on KDM2A controlling cell proliferation are varied among cell types, even controversial conclusions have been drawn. In order to elucidate the functions and underlying mechanisms for KDM2A controlling cell proliferation and apoptosis, we screened a KDM2A knockout HEK293T cell lines by CRISPR-Cas9 to illustrate the effects of KDM2A on both biological process. The results indicate that knocking down expression of KDM2A can significantly weaken HEK293T cell proliferation. The cell cycle analysis via flow cytometry demonstrate that knockdown expression of KDM2A will lead more cells arrested at G2/M phase. Through the RNA-seq analysis of the differential expressed genes between KDM2A knockdown HEK293T cells and wild type, we screened out that TGF-β pathway was significantly downregulated in KDM2A knockdown cells, which indicates that TGF-β signaling pathway might be the downstream target of KDM2A to regulate cell proliferation. When the KDM2A knockdown HEK293T cells were transient-transfected with KDM2A overexpression plasmid or treated by TGF-β agonist hydrochloride, the cell proliferation levels can be partial or completely rescued. However, the TGF-β inhibitor LY2109761 can significantly inhibit the KDM2A WT cells proliferation, but not the KDM2A knockdown HEK293T cells. Taken together, these findings suggested that KDM2A might be a key regulator of cell proliferation and cell cycle via impacting TGF-β signaling pathway.
Wen-Hao Xu, Da-Yan Liang, Qi Wang, Jinhua Shen, Qing-Hua Liu, Yong-Bo Peng

2917 related Products with: Knockdown of KDM2A inhibits proliferation associated with TGF-β expression in HEK293T cell.

25 ml.100 ml.100ug Lyophilized0.5 mg96 samples2500 assays

Related Pathways

paperclip

#30464460   2018/11/02 To Up

Stearyl polyethylenimine complexed with plasmids as the core of human serum albumin nanoparticles noncovalently bound to CRISPR/Cas9 plasmids or siRNA for disrupting or silencing PD-L1 expression for immunotherapy.

In this study, a double emulsion method for complexing plasmids with stearyl poly-ethylenimine (PEI) as the core to form human serum albumin (HSA) (plasmid/PEI/HSA) nanoparticles (NPs) was developed for gene delivery by non-covalently binding onto plasmid/PEI/HSA nanoparticles with CRISPR/Cas9 or siRNA, which disrupts or silences the expression of programmed cell death ligand-1 (PD-L1) for immunotherapy.
Wei-Jie Cheng, Ling-Chun Chen, Hsiu-O Ho, Hong-Liang Lin, Ming-Thau Sheu

2649 related Products with: Stearyl polyethylenimine complexed with plasmids as the core of human serum albumin nanoparticles noncovalently bound to CRISPR/Cas9 plasmids or siRNA for disrupting or silencing PD-L1 expression for immunotherapy.



Related Pathways

paperclip

#23812961   2013/06/28 To Up

Relative bioequivalence evaluation of two oral atomoxetine hydrochloride capsules: a single dose, randomized, open-label, 2-period crossover study in healthy Chinese volunteers under fasting conditions.

To evaluate the bioequivalence of a new formulation of atomoxetine hydrochloride (CAS 82248-59-7) capsules (test) and an available branded capsules (reference) after administration of a single 40 mg dose, randomized, open-label, 2-period crossover study was conducted in 22 healthy male Chinese subjects with a 1-week wash-out period. This study was designed for/the Honglin Pharmaceutical Co. Ltd and contracted to be done by the Beijing Anding Hospital in order to satisfy Chinese regulatory requirements to allow marketing of this generic product and performed according to the criteria of SFDA. Blood samples were collected before and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16 and 24 h after drug administration. Plasma concentrations were determined by high-performance liquid chromatography (HPLC) with UV detection. A non-compartmental method was used to calculate the pharmacokinetic parameters and evaluate bioequivalence of the 2 formulations. The 90% confidence interval (CI) of the ratios (test/reference) of atomoxetine for AUC0-24, AUC0-∞ and Cmax were 100.9% (93.6-108.8%), 103.1% (95.1-111.7%) and 105.2% (92.8-119.4%), respectively, which fell within the interval of 80-125% and 75-133%. No clinically significant changes or abnormalities were noted in laboratory data and vital signs. From these results it can be concluded that the test formulation of atomoxetine capsules met the regulatory criterion for bioequivalence to the reference formulation.
D-W Shang, W Guo, F-C Zhou, X-P Wang, A-N Li, L Zhang, W-B Li, W Lu, C-Y Wang

1375 related Products with: Relative bioequivalence evaluation of two oral atomoxetine hydrochloride capsules: a single dose, randomized, open-label, 2-period crossover study in healthy Chinese volunteers under fasting conditions.

10 mg5 mg5 mg1 mg1 mg50 1 Set1 Set100ug Lyophilized

Related Pathways

paperclip

#23046695   2012/09/04 To Up

Guanidylated hollow fiber membranes based on brominated poly (2,6-dimethyl-1,4-phenylene oxide) (BPPO) for gold sorption from acid solutions.

Novel guanidylated hollow fiber membranes are prepared based on brominated poly (2,6-dimethyl-1,4-phenylene oxide) (BPPO) under mild reaction conditions. 1H-pyrazole-1-carboxamidine hydrochloride (HPCA) is employed for the guanidylation in aqueous solution at room temperature. The obtained guanidylated PPO hollow fiber membranes (GPPO HFMs) contain 0.31-0.95 mmol/g guanidyl groups and show high affinity to tetrachloroauric anions (AuCl(4)(-)) in acid solutions. For 0.1M HCl solution containing 57.8 mg gold/L, the sorption amount can get as high as 130 mg/g. Besides, the GPPO HFMs show preferable selectivity toward gold in multicomponent solution containing Mg(II), Fe(III), Co(II), Ni(II), Cu(II), Zn(II) and Pb(II). A system of comparison experiments involving the sorption behavior of GPPO HFMs and quaternary aminated HFMs are also performed. The results reveal that driving forces for the high adsorption of gold mainly involve complexation mechanism. Overall, the obtained GPPO HFM is a promising chelating material for the recovery of gold.
Jin Ran, Na Wang, Xue You, Cuiming Wu, Qiuhua Li, Ming Gong, Tongwen Xu

1797 related Products with: Guanidylated hollow fiber membranes based on brominated poly (2,6-dimethyl-1,4-phenylene oxide) (BPPO) for gold sorption from acid solutions.

100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized8500 mg100ug100ug100ug Lyophilized100ug Lyophilized0,2100ug

Related Pathways

paperclip

#22791244   2012/07/12 To Up

Comparative fasting bioavailability and pharmacokinetic properties of 2 formulations of glucosamine hydrochloride in healthy Chinese adult male volunteers.

Glucosamine (CAS 66-84-2) hydrochloride is an amino monosaccharide indicated for the treatment of arthrosis, especially osteoarthritis of the knee joint. This study was conducted to assess and compare the pharmacokinetic (PK) properties, bioavailability of a newly developed dispersible tablet formulation (test) of glucosamine hydrochloride with those of an established branded capsule formulation (reference) in healthy Chinese adult male volunteers.This single-dose, randomized, open-label, 2-period crossover study was conducted in 18 healthy Chinese adult male volunteers under fasting condition. Plasma samples were collected at pre-specified times over a 12-h period following administration in each period and analyzed the plasma glucosamine concentrations by Liquid Chromatography coupled with Tandem Mass Spectrometry (LC/MS/MS) method. The mean (SD) PK parameters of Cmax, Tmax, AUC0-12, and AUC0-∞ after administration of the test and reference formulations were, respectively, as follows: Cmax, 907.01 (444.22) vs. 944.40 (429.89) ng/mL, Tmax, 3.03 (0.95) vs. 3.30 (0.99) hours, AUC0-12, 2891.41 (1352.30) vs. 2889.69 (925.48) ng/mL/h, and AUC0-∞, 3029.90 (1321.36) vs. 3091.87 (870.36) ng/mL/h. The mean (SD) t1/2 was 1.10 (0.52) hours for the test formulation and 1.50 (1.17) hours for the reference formulation. On ANOVA, neither period nor sequence effects were observed for any PK properties. The relative bioavailability of the test formulation was 98.3% assessed by AUC0-12. The 90% CIs of glucosamine for the log-transformed ratios of Cmax, AUC0-12, and AUC0-∞ were 78.4-113.9%, 80.8-108.5% and 80.8-105.8%, respectively, meeting the predetermined criteria for bioequivalence of SFDA.
H Wu, M Liu, S Wang, H Zhao, W Yao, W Feng, M Yan, Y Tang, M Wei

2414 related Products with: Comparative fasting bioavailability and pharmacokinetic properties of 2 formulations of glucosamine hydrochloride in healthy Chinese adult male volunteers.

250ul10 500 G250ul5 g 1 G5 g5 g 25 G10mg100ug Lyophilized20mg

Related Pathways

paperclip

#22029232   // To Up

Comparative pharmacokinetics study of two different clindamycin capsule formulations: a randomized, two-period, two-sequence, two-way crossover clinical trial in healthy volunteers.

The comparative pharmacokinetic (PK) study of two brands of clindamycin hydrochloride (CAS 21462-39-5) was carried out on 32 healthy Indian subjects in an open label randomized, two way crossover, two period, two sequence, two treatment trial with a minimum washout period of 7 days. Plasma samples were collected at 10 min interval for the 1st hour, at 1 h interval for the next 6 h, at 2 h interval for next 12 h and finally at the 24th hour (pre-dose as baseline value) after drug administration. The concentrations of clindamycin in plasma were determined using high performance liquid chromatography (HPLC) technique with UV detector [lower limit of quantitation (LLOQ) 0.05 microg x mL(-1)). All PK parameters were calculated from data on clindamycin content in plasma using a non-compartmental model. Primary PK parameters were maximum plasma concentration (Cmax), area under the curve from zero to t(th) hour (AUCT) and area under the curve from zero to infinite (AUCI), whereas secondary PK parameters were elimination half-life (t half), elimination rate constant (K el) and time to reach maximum plasma concentration (Tmax). All primary PK parameters (log transformed) were subjected to ANOVA analysis and two one-sided Student's t-test (TOST) to construct the 90% confidence intervals. The result of ANOVA showed that all primary PK parameters at 90% confident intervals were within the limit of 80-125%. All the values such as 95.7-109.00% for Cmax, 99.5-117% for AUCT and 99.1% to 114% for AUCI showed pharmacokinetic equivalence and indicated that this comparative pharmacokinetic study was well designed to conclude that the test formulation and reference formulation were pharmacokinetically equivalent and hence bioequivalent with respect to rate and extent of absorption.
Utpal Kumar Sanki, Badal Kumar Mandal, Venkatesh Chandrakala

2974 related Products with: Comparative pharmacokinetics study of two different clindamycin capsule formulations: a randomized, two-period, two-sequence, two-way crossover clinical trial in healthy volunteers.



Related Pathways

paperclip

#19998578   // To Up

Therapeutic properties and tolerance of procaine and phenazone containing ear drops in infants and very young children.

Since ear pain is often intolerable in very young children with acute otitis media (AOM), a safe pain reduction is indispensable both from the medical as well as from the ethical point of view.
Dieter Adam, Pierre Federspil, Martin Lukes, Otto Petrowicz

2464 related Products with: Therapeutic properties and tolerance of procaine and phenazone containing ear drops in infants and very young children.

100 mg2.5 mg 25 MG100ul25 mg50 ug 200ug10 mg25 mg1000 tests100ul

Related Pathways

paperclip

#19819565   2009/09/16 To Up

Chronic effects assessment and plasma concentrations of the beta-blocker propranolol in fathead minnows (Pimephales promelas).

The presence of many human pharmaceuticals in the aquatic environment is now a worldwide concern, yet little is known of the chronic effects that these bioactive substances may be having on aquatic organisms. Propranolol, a non-specific beta adrenoreceptor blocker (beta-blocker), is used to treat high blood pressure and heart disease in humans. Propranolol has been found in surface waters worldwide at concentrations ranging from 12 to 590ng/L. To test the potential for ecologically relevant effects in fish in receiving waters, short-term (21 days) adult reproduction studies were conducted, in which fathead minnows were exposed to nominal concentrations of propranolol hydrochloride [CAS number 318-98-9] ranging from 0.001 to 10mg/L (measured concentrations typically from 78 to 130%). Exposure of fish to 3.4mg/L (measured) over 3 days caused 100% mortality or severe toxicity requiring euthanasia. The most sensitive endpoints from the studies were a decrease in hatchability (with regard to the number of days to hatch) and a concentration-related increase in female gonadal somatic index (GSI), giving LOEC(hatchability) and LOEC(female GSI) values of 0.1mg/L. Concentration-related decreases in weights of male fish were also observed, with LOEC(male wet weight value) of 1.0mg/L, and the LOEC(reproduction) value was 1.0mg/L. Collectively, these data do not suggest that propranolol was acting as a reproductive toxin. Plasma concentrations of propranolol in male fish exposed to nominal concentrations of 0.1 and 1.0mg/L were 0.34 and 15.00mg/L, respectively, which constitutes 436 and 1546% of measured water concentrations. These compare with predicted concentrations of 0.07 and 0.84mg/L, and thus to a degree support the use of partition coefficient models for predicting concentrations in plasma in fish. In addition, propranolol plasma concentrations in fish exposed to water concentrations of 0.1 and 1.0mg/L were greater than the human therapeutic plasma concentration and hence these data very strongly support the fish plasma model proposed by Huggett et al. [Huggett, D.B., Cook, J.C., Ericson, J.F., Williams, R.T., 2003a. A theoretical model for utilizing mammalian pharmacology and safety data to prioritize potential impacts of human pharmaceuticals to fish. Hum. Ecol. Risk Assess. 9, 1789-1799].
Emma Giltrow, Paul D Eccles, Matthew J Winter, Paul J McCormack, Mariann Rand-Weaver, Thomas H Hutchinson, John P Sumpter

1294 related Products with: Chronic effects assessment and plasma concentrations of the beta-blocker propranolol in fathead minnows (Pimephales promelas).

100 MG100ug100.00 ug100ug Lyophilized0.05 mg100ug0.1 mg100ug Lyophilized100ug

Related Pathways

paperclip

#19402342   // To Up

Quantitative determination of ticlopidine hydrochloride in human plasma by high-performance liquid chromatography-electronspray ionization mass spectrometry.

A sensitive, selective and simple high performance liquid chromatographyelectrospray ionization-mass spectrometry (HPLC-ESI-MS) was developed and validated for the quantification of ticlopidine hydrochloride (CAS 53885-35-1) in human plasma using loratadine (CAS 79794-75-5) as internal standard (IS). Following liquid-liquid extraction, the analyte and the IS were extracted from plasma samples by n-hexane:isopropanol (95:5, v/v), separated by HPLC on a commercially available column (150 mm x 2.0 mm ID, 5 microm) with a mobile phase of acetonitrile: 10 mmol/L ammonium acetate buffer solution (85:15, v/v) and analyzed on a quadrupole mass spectrometer with ESI interface operating in the positive-ion mode. The correlation coefficient of the calibration curve was linear (r2 > 0.99) over the concentration range of 1-1000 ng/mL for ticlopidine hydrochloride. The intra- and inter-batch precisions were less than 15% of the relative standard deviation and the accuracy ranged from 85 to 115% in terms of percent accuracy. The limit of detection (LOD) of ticlopidine hydrochloride was 0.5 ng/mL. The extraction recovery of ticlopidine hydrochloride was more than 80%. The proposed method enables the unambiguous identification and quantification of ticlopidine hydrochloride for pharmacokinetic, bioavailability or bioequivalence studies.
Jing Sun, Haoyan Jiao, Yuan Tian, Zunjian Zhang, Yun Chen

2460 related Products with: Quantitative determination of ticlopidine hydrochloride in human plasma by high-performance liquid chromatography-electronspray ionization mass spectrometry.

16 Arrays/Slide96T1 kit1 mg5 mg96 wells (1 kit)96 wells (1 kit)1 mg96 wells (1 kit)400Tests16 Arrays/Slide96 wells (1 kit)

Related Pathways

paperclip

#12785126   // To Up

Clinical relevance of bioequivalence acceptance criteria. The example of terbinafine.

The present study was conducted with the aim of investigating which acceptance criteria for bioequivalence are relevant for orally applied antimycotics using terbinafine (CAS 78628-80-5) as an example.
Rossen Koytchev, Aydin Erenmemisoglu, Mike John van der Meer, Serdar Alpan

1089 related Products with: Clinical relevance of bioequivalence acceptance criteria. The example of terbinafine.

5 Gmin 2 cartonsML

Related Pathways

    No related Items